Skip to content
Sign in
Artwork for Stock Movers
Stock Movers · Yesterday · 2 min

GSK Jumps, Astrazeneca Up

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - GSK announced that its Jideytro (zidesamtinib) achieved a 94% objective response rate in TKI-naïve ROS1-positive non-small cell lung cancer patients in the registrational phase I/II ARROS-1 trial, with no placebo comparator. - AstraZeneca’s breast-cancer pill trial failure could cut several billion dollars from the drug’s potential sales, according to analysts. See omnystudio.com/listener for privacy information.

0:00-2:53
Play in
Transcript file

transcript

No transcript — this publisher did not publish one.

show notes

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- GSK announced that its Jideytro (zidesamtinib) achieved a 94% objective response rate in TKI-naïve ROS1-positive non-small cell lung cancer patients in the registrational phase I/II ARROS-1 trial, with no placebo comparator.
- AstraZeneca’s breast-cancer pill trial failure could cut several billion dollars from the drug’s potential sales, according to analysts.

See omnystudio.com/listener for privacy information.

links1

more episodes

All episodes